NEO — Neogenomics Cashflow Statement
0.000.00%
Last trade - 00:00
- $1.94bn
- $2.06bn
- $591.64m
- 71
- 40
- 85
- 72
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 8.01 | 4.17 | -8.35 | -144 | -88 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 17.5 | 23.3 | -66.7 | 40.5 | 38.9 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -32.4 | -61.7 | -4.99 | -31.7 | -25.5 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 23.4 | 1.46 | -26.7 | -66 | -1.95 |
Capital Expenditures | -20 | -29.1 | -64.1 | -30.9 | -28.8 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 0.399 | -130 | -568 | 31.4 | 105 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -19.6 | -159 | -632 | 0.517 | 76.7 |
Financing Cash Flow Items | -1.06 | -3.32 | -29.3 | 0 | 0 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 159 | 236 | 725 | 11.8 | 4.55 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 163 | 77.6 | 66.2 | -53.6 | 79.3 |